Corporate boards are built to manage risk, evaluate performance, and protect a company’s interests. What most boards are not built to do, and often actively avoid doing, is have a direct conversation about a CEO’s substance use. When signs point toward a real problem, the typical response isn’t confrontation or a structured plan. It’s silence, deflection, and a hope that the situation resolves itself before it becomes anyone’s official responsibility to address.
This gap between what should happen and what actually happens carries real consequences, for the company, for shareholders, and for the CEO themselves.
Why Boards Tend to Avoid the Conversation
Several forces work against boards addressing this directly. There’s a legal and reputational sensitivity around discussing an executive’s health that makes many board members and general counsel cautious about anything that could be construed as a health related decision. There’s also a practical hesitation rooted in uncertainty. Board members are rarely equipped to distinguish between a stressful period, a personal crisis, and an active substance use disorder, and getting that assessment wrong carries its own risk of overreach or legal exposure.
There’s also a simpler, more human reason. Confronting a CEO, particularly one who has built real credibility and success, is uncomfortable. It can feel presumptuous, invasive, or like an accusation that damages a working relationship regardless of whether concerns turn out to be accurate. Many boards choose the path of least resistance, which usually means continuing to monitor informally rather than raising the issue directly.
The Signs That Typically Get Noticed First
Long before a board formally acknowledges a concern, certain patterns tend to surface. Erratic decision making that doesn’t match a CEO’s usual judgment. Noticeable changes in communication style, whether that’s uncharacteristic irritability, disorganized presentations, or missed commitments that wouldn’t previously have happened. Unexplained absences or late arrivals to meetings that matter. Behavior during travel or evening events that colleagues quietly discuss but don’t formally report.
Individually, any of these signs could reflect something else entirely, stress, a personal matter, a demanding stretch of the business cycle. That ambiguity is part of why boards struggle to act. Nobody wants to raise a serious concern based on evidence that might have an innocent explanation, so the pattern often continues until something more visible forces the issue, a public incident, a serious business misstep, or a direct complaint from someone within the company.
What a More Proactive Response Would Look Like
A more effective approach starts well before any confirmed problem, with clear governance structures already in place. This includes a defined process for how the board would address concerns about any executive’s fitness to serve, established in advance rather than improvised during an actual crisis. Some boards build this into broader executive wellness or succession planning policies, which normalizes the existence of a process without singling out any individual.
When specific concerns do arise, a structured response generally involves a small subset of board members, often the lead independent director or a designated committee, having a direct, private, and non-punitive conversation with the CEO. The goal at this stage isn’t discipline. It’s an honest check-in that communicates genuine concern alongside a clear statement that support, not punishment, is the board’s priority if something real is going on.
This conversation works best when it’s specific rather than vague, referencing concrete observed patterns rather than general unease, and when it comes from a place of protecting both the company and the individual rather than positioning the two as being in conflict.
Why Professional Assessment Matters More Than Board Judgment
Boards are not equipped to diagnose a substance use disorder, and they shouldn’t try to. What a well handled process typically includes is a referral to an independent, confidential professional assessment, sometimes through an employee assistance program if one exists at the executive level, or through an outside occupational health professional experienced in executive evaluations.
This step matters because it removes board members from the position of making a clinical judgment they aren’t qualified to make, while still ensuring that a genuine concern gets a real answer rather than being dismissed or ignored. If an assessment identifies a substance use disorder, especially one involving a co-occurring condition, this is also where the process should account for dual diagnosis treatment specifically, since executives under significant occupational stress are not immune to conditions like dual diagnosis anxiety, where substance use and an underlying anxiety disorder develop and reinforce each other over time.
Balancing Confidentiality With Fiduciary Responsibility
This is where boards face a genuine tension. Executives, like anyone, are generally entitled to privacy regarding health matters, and premature disclosure can cause real harm, both personally and to a company’s stock price or public confidence, especially if concerns turn out to be overstated. At the same time, boards have a fiduciary duty to shareholders that can require disclosure if a CEO’s condition materially affects their ability to lead or creates undisclosed risk to the company.
Navigating this generally requires legal counsel experienced in executive governance, working alongside whatever confidential assessment and treatment process is already underway. There’s no universal formula here, since the right balance depends on the specific facts, the company’s disclosure obligations, and how directly the situation affects business operations or decision making.
What Treatment Access Should Look Like for Executives
When treatment does happen, the level of care needs to match clinical necessity, the same as it would for anyone, rather than being shaped primarily around discretion or public image. That said, reputable addiction treatment centers do offer arrangements that account for legitimate privacy needs without compromising clinical quality. This might include coordinated planning around timing, communication protocols with the company, and integration with outpatient mental health treatment upon return to work, particularly if a co-occurring condition requires ongoing management rather than a single treatment episode.
A CEO returning to their role after treatment benefits from a defined reentry plan, ideally developed with input from the treatment team, that addresses workload, support structures, and realistic expectations during an early recovery period that carries its own risks, including a genuinely elevated risk of relapse in the months immediately following treatment.
Why Getting This Right Matters Beyond One Individual
How a board handles this situation sends a signal throughout an entire organization about how seriously health issues, including addiction, are taken at every level. A board that avoids the conversation entirely, or handles it punitively rather than supportively, reinforces exactly the kind of stigma that keeps people at every level of a company from seeking help early. A board that handles it thoughtfully, with genuine concern, appropriate professional referral, and a real path back to leadership, models something valuable that extends well beyond the executive suite.
The Bottom Line
What should happen when a board suspects a CEO has a substance problem is a structured, confidential, professionally guided response built on genuine concern rather than avoidance or punishment. What actually tends to happen is silence, discomfort, and delay, often until a crisis forces the issue into the open. Closing that gap requires boards to build governance processes before they’re needed, treat substance use as the health issue it is, and understand that addiction recovery, including coordinated dual diagnosis treatment when relevant, works best when it starts well before a public failure makes the decision for everyone involved.
